title: Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis.
abstract: OBJECTIVE
  To explore whether TNF-α promoter -308 A/G and -857 C/T polymorphisms have an association with responsiveness to TNF blockers in spondyloarthritis and inflammatory bowel disease.
  
  
  METHODS
  A meta-analysis was performed. Pooled odds ratios (ORs) and 95% CIs were calculated.
  
  
  RESULTS
  Six relevant studies with a total of 211 spondyloarthritis patients and 392 inflammatory bowel disease patients were included. The results showed that the common allele (G and C, respectively) showed a better responsiveness than the minor allele (A and T, respectively). The -308 G/G genotype (OR: 2.31; 95% CI: 1.36-3.91; p = 0.002) and -857 C/C genotype (OR: 3.66; 95% CI: 1.35-9.92; p = 0.01) responded better to therapy, which was different from the results of some studies included.
  
  
  CONCLUSIONS
  Individuals with the TNF-α-308 G allele and -857 C allele showed better anti-TNF-α treatment responses than those with the TNF-α-308 A allele and -857 T allele. The -308 G/G genotype and -857 C/C genotype are predictors of good response.
authors.affiliation: Department of Rheumatology & Immunology, Changhai Hospital, Second Military Medical University, Yangpu District, No. 168 Changhai Road, Shanghai 200433, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Tong
authors.forename: Liang
authors.initials: L
authors.lastname: Zhao
authors.forename: Xiao-Di
authors.initials: XD
authors.lastname: Qian
authors.forename: Lan-Ling
authors.initials: LL
authors.lastname: Zhang
authors.forename: Xia
authors.initials: X
authors.lastname: Xu
authors.forename: Sheng-Ming
authors.initials: SM
authors.lastname: Dai
authors.forename: Qing
authors.initials: Q
authors.lastname: Cai
authors.forename: Dong-Bao
authors.initials: DB
authors.lastname: Zhao
mesh_terms: D000068879:Adalimumab; D000483:Alleles; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068800:Etanercept; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept